- Home
- DHT vs EWTX Comparison
DHT vs EWTX Comparison
Compare DHT & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DHT
- EWTX
- Stock Information
- Founded
- DHT 2005
- EWTX 2017
- Country
- DHT Bermuda
- EWTX United States
- Employees
- DHT N/A
- EWTX N/A
- Industry
- DHT Marine Transportation
- EWTX Biotechnology: Pharmaceutical Preparations
- Sector
- DHT Consumer Discretionary
- EWTX Health Care
- Exchange
- DHT Nasdaq
- EWTX Nasdaq
- Market Cap
- DHT 1.9B
- EWTX 1.6B
- IPO Year
- DHT 2005
- EWTX 2021
- Fundamental
- Price
- DHT $13.35
- EWTX $23.66
- Analyst Decision
- DHT Strong Buy
- EWTX Buy
- Analyst Count
- DHT 3
- EWTX 10
- Target Price
- DHT $15.67
- EWTX $37.30
- AVG Volume (30 Days)
- DHT 2.0M
- EWTX 1.3M
- Earning Date
- DHT 10-29-2025
- EWTX 11-06-2025
- Dividend Yield
- DHT 6.92%
- EWTX N/A
- EPS Growth
- DHT 23.62
- EWTX N/A
- EPS
- DHT 1.24
- EWTX N/A
- Revenue
- DHT $538,571,000.00
- EWTX N/A
- Revenue This Year
- DHT N/A
- EWTX N/A
- Revenue Next Year
- DHT $38.90
- EWTX N/A
- P/E Ratio
- DHT $11.07
- EWTX N/A
- Revenue Growth
- DHT N/A
- EWTX N/A
- 52 Week Low
- DHT $8.67
- EWTX $10.60
- 52 Week High
- DHT $13.85
- EWTX $35.50
- Technical
- Relative Strength Index (RSI)
- DHT 56.14
- EWTX 75.81
- Support Level
- DHT $13.27
- EWTX $21.72
- Resistance Level
- DHT $13.80
- EWTX $23.36
- Average True Range (ATR)
- DHT 0.37
- EWTX 1.49
- MACD
- DHT -0.04
- EWTX 0.32
- Stochastic Oscillator
- DHT 54.29
- EWTX 95.62
About DHT DHT Holdings Inc.
DHT Holdings Inc is a crude oil tanker company. Its fleet trades internationally and consists of crude oil tankers in the VLCC. The group generates revenues from time charter and spot market operations. It operates through integrated management companies in Monaco, Norway, Singapore, and India. The company generates the majority of its revenue from the shipping revenues.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.